Oncology CDK9 inhibitors: Disrupting cancer cell growth and the treat... We have made significant strides in cancer treatment in the last decade and a half.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
